<ѻý>Trump-Era Conscience Rule Rescinded; Lloyd Austin's Cancer; Sinead O'Connor's Deathѻý> Health news and commentary from around the Web gathered by ѻý staff Jan 10, 2024
<ѻý>More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effectsѻý> Meta-analysis shows increased risk of dementia, Parkinson's, depression Jan 09, 2024
<ѻý>Testosterone for Hypogonadism Cleared So Far of Prostate Cancer Riskѻý> No excess high-grade or overall prostate cancer risk in TRAVERSE with 33 months of follow-up Dec 27, 2023
<ѻý>TULSA Effective in Controlling Prostate Cancer Long-Termѻý> At 5 years, median PSA was reduced by 90% Dec 05, 2023
<ѻý>Diagnostic Imaging Not Yet Enough for Biopsy-Free Radical Prostatectomyѻý> Study validates concerns about benign prostatic hyperplasia-related PSMA-PET false positives Nov 27, 2023
<ѻý>Moving Beyond the 'Angelina Jolie Effect' to Address Cancer Disparitiesѻý> A "local heroes effect" can better reach communities of color Nov 09, 2023
<ѻý>Transitioning Cancer Survivors Away From Oncologic Careѻý> It's time for a new model of care Nov 03, 2023
<ѻý>Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPCѻý> Grade 3 or higher neutropenia, neutropenic complications reduced by 12-fold Nov 01, 2023
<ѻý>Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPCѻý> Time to radiographic progression doubled with 177Lu-PSMA-617 Oct 25, 2023
<ѻý>Carbohydrates and Long-Term Weight Change; Value of Cardiac Transfersѻý> Also in TTHealthWatch: reducing infections in joint replacement Oct 21, 2023 podcast
<ѻý>Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?ѻý> It's time for clear guidelines Oct 18, 2023
<ѻý>SBRT Noninferior to Conventional RT for Intermediate-Risk Prostate Cancerѻý> Treatment over 1 to 2 weeks achieves similar outcomes to therapy given for as long as 7.5 weeks Oct 03, 2023
<ѻý>SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic Prostate Cancerѻý> Combination improved biochemical response and PFS compared with systemic treatment alone Sep 27, 2023
<ѻý>Global Incidence of Early-Onset Cancer Has Surged Since 1990ѻý> Early-onset breast cancer has highest incidence and mortality rates Sep 06, 2023
<ѻý>Prostate Cancer Is Not Just an 'Old Man's Disease'ѻý> Spreading this message can save lives Sep 02, 2023
<ѻý>Does Cancer Screening Actually Extend Lives?ѻý> A series of articles look at whether the benefits for the few warrant the harms for the many Aug 28, 2023
<ѻý>Multi-Cancer Early Detection: 20th-Century Fiction Becomes Realityѻý> These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
<ѻý>MR-Guided Adaptive SBRT Tied to Reduced Side Effects in Prostate Cancerѻý> However, this technique requires more time and resources than standard techniques Jul 24, 2023
<ѻý>FDA OKs Olaparib-Abiraterone for Metastatic Prostate Cancerѻý> Approval limited to BRCA-positive subset Jun 01, 2023
<ѻý>Lumpers vs Splitters: Categorizing Prostate Cancerѻý> Should very low-risk and low-risk be combined into one? May 19, 2023
<ѻý>Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancerѻý> Combo has potential to be new standard of care in patients with high-risk BCR, expert says Apr 30, 2023
<ѻý>FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPCѻý> ODAC votes that olaparib-abiraterone combination should be restricted to BRCA-positive subset Apr 28, 2023
<ѻý>Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancerѻý> All but one patient had a PSA decline after a fractionated dose of 225Ac-J591 Apr 18, 2023
<ѻý>Older Men Still Overscreened for Prostate Cancer, Survey Saysѻý> PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it Apr 11, 2023
<ѻý>Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomyѻý> But add-on abiraterone and apalutamide may offer some benefits in those with higher PSA Feb 18, 2023
<ѻý>Add-On Olaparib Continues to Show Benefit in First-Line Treatment of mCRPCѻý> Final PROpel analysis also shows trend toward overall survival improvement with PARP inhibitor Feb 17, 2023
<ѻý>Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancerѻý> Combination achieved a 37% reduction in risk of progression, death versus ARPI alone Feb 17, 2023
<ѻý>Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancerѻý> Benefit in selected patients seen over physician's choice of docetaxel or second-generation ARPI Feb 16, 2023
<ѻý>If It Resembles Cancer but Doesn't Act Like Cancer, Is It Cancer?ѻý> Physicians must consider patient perspectives on the Gleason 6 debate Feb 16, 2023
<ѻý>Short-Course Apalutamide to Reduce Active Surveillance Attrition in Prostate Cancerѻý> Editorialists question whether any intervention violates principles of surveillance Jan 17, 2023
<ѻý>MRI-Guided Focused Ultrasound Eases Pain From Bone Metastasesѻý> More responses with ultrasound, but quality-of-life scores lower vs EBRT in nonrandomized trial Jan 11, 2023
<ѻý>MRI-Targeted Biopsy for Prostate Cancer Reduces Risk of Overdiagnosisѻý> Though at the cost of delayed diagnosis of some clinically significant cancers Dec 07, 2022
<ѻý>Can Oncologists Reduce the Suicide Risk in Their Prostate Cancer Patients?ѻý> Barriers exist in identifying risk, but strategies are available Dec 06, 2022
<ѻý>Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancerѻý> Surgery or radiation delayed initiation of systemic therapy by 18 months Nov 29, 2022
<ѻý>Primary Care Visits Prior to Cancer Diagnosis Tied to Lower Mortalityѻý> Most benefit with annual visits, but even some use linked to better outcomes Nov 16, 2022
<ѻý>Could a Plant-Based Diet Benefit Men's Health Below the Belt?ѻý> Analysis suggests protective nature of veggie-heavy diet in prostate cancer and more Oct 30, 2022
<ѻý>Metastasis-Directed Therapy for Prostate Cancer Increases PFS, Time off Hormonesѻý> Radiotherapy led to "dramatic" slowing of progression, increased time with normal testosterone Oct 27, 2022
<ѻý>Sexual Health Not Part of Discussion for Women Undergoing Brachytherapyѻý> Much less likely than men to be queried about sexual function when receiving treatment Oct 25, 2022
<ѻý>Shorter Course of Radiation Therapy Proves Mettle in High-Risk Prostate Cancerѻý> Hypofractionation matches standard RT for survival and toxicity in a third less time Oct 25, 2022
<ѻý>Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancerѻý> Will USPSTF's 2018 guidelines reverse this trend? Oct 25, 2022